GLP-1s Reduce Heavy Drinking Days in Patients With Obesity, Alcohol Use Disorder

Why It Matters

The findings suggest semaglutide could become the first GLP‑1 therapy approved for alcohol use disorder, expanding treatment options beyond the three existing FDA‑approved drugs and addressing a major comorbidity of obesity.

Key Takeaways

• Semaglutide cut heavy‑drinking days by 41.1% vs 26.4% placebo.
• Participants lost 11.2 kg on semaglutide, versus 2.2 kg with placebo.
• Gastrointestinal side effects led to five discontinuations, one serious event.
• Study enrolled 108 obese adults with AUD; 88 completed 26‑week trial.
• First RCT showing GLP‑1 RA reduces alcohol consumption and weight.

Pulse Analysis

Alcohol use disorder (AUD) remains a public‑health challenge, with only three FDA‑approved pharmacotherapies and a heavy reliance on behavioral counseling. Meanwhile, glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs) such as semaglutide have reshaped obesity and type‑2 diabetes treatment by modulating appetite pathways in the brain. Researchers have long speculated that these same neural circuits could curb cravings for alcohol, prompting a wave of pre‑clinical studies that set the stage for human trials.

The Copenhagen trial enrolled 108 adults with a body‑mass index of 30 kg/m² or higher and a diagnosis of AUD, randomizing them to weekly 2.4 mg semaglutide or placebo for 26 weeks. Participants receiving semaglutide reduced heavy‑drinking days by 41.1 percentage points, outpacing the 26.4‑point decline in the control group, and cut monthly alcohol consumption by roughly 1.55 kg. Weight loss was pronounced—11.2 kg versus 2.2 kg—highlighting the drug’s dual benefit. Adverse events were largely gastrointestinal, with five withdrawals and a single serious abdominal episode, mirroring the safety profile observed in obesity indications.

If regulators extend semaglutide’s label to include AUD, the market could see a paradigm shift: a single injection that tackles both excess weight and harmful drinking. Pharmaceutical firms may accelerate development of next‑generation GLP‑1 analogues tailored for addiction, while insurers could reassess coverage policies to reflect broader therapeutic value. Ongoing studies will need to address long‑term sobriety outcomes and diverse patient populations, but the current data provide a compelling proof‑of‑concept that could reshape treatment algorithms for millions of Americans struggling with co‑occurring obesity and alcohol misuse.